Just Released: "Orphan Drugs: Rescue from the Patent Cliff"

New Pharmaceuticals market report from MarketLine: "Orphan Drugs: Rescue from the patent cliff"


Boston, MA -- (SBWire) -- 01/17/2014 --Orphan drugs treat diseases that affect fewer than 1 in 2,000 Europeans & fewer than 200,000 Americans. Research into orphan drugs benefits from incentives provided by the 1983 Orphan Drug Act, such as tax breaks, faster regulatory reviews and assistance from FDA reviewers. Orphan drugs are less likely to face competition and provide a high return on investment. Cinryze costs $487,000 annually.

Features and benefits

- This reports looks at big pharma and how it has been affected by the patent cliff and the patent-loss of many of its biggest-selling blockbuster drugs
- Orphan drugs are granted certain incentives at the development stage, which encourages Big Pharma to invest in them.
- Orphan drugs can be very lucrative as companies can charge a large amount for them. Much of the costs are covered by governments/insurance companies


Global orphan drug sales increased at a rate of 7.1% to be worth $83bn in 2012 compared to the previous year. Orphan drugs are expected to bring in revenues of $127bn by 2018 and will account for almost 16% of total prescription drug sales, compared to 12.9% in 2012.
The most expensive drug in the world in 2013, Cinryze, is used by patients with hereditary angioedema, and is sold by ViroPharma. The drug's annual cost per patient is $487,000 per year. The second most expensive drug, Soliris, is sold by Alexion Pharmaceuticals, treats patients with paroxysmal nocturnal hemoglobinuria, & costs $486,000 annually.
According to patient advocacy group, Eurodis, around one third of EU patients can't get access to, or have difficulty accessing, the orphan drug they need.

View Full Report Details and Table of Contents

Your key questions answered

- What drugs have lost their patents/are due to lose their patents, and what are they worth?
- Why is the orphan drug market attractive to pharmaceuticals companies?
- How have companies attempted to enter this market?
- Are the high prices of orphan drugs sustainable?

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Orphan Drugs Partnering Terms and Agreements
- The Orphan Drug Market Outlook to 2017
- Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat
- Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs
- Alexion Pharmaceuticals, Inc.: Focus on ultra-rare diseases as a revenue and profit driver
- Swedish Orphan Biovitrum AB (SOBI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
- HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth
- Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
- Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff

Media Relations Contact

Bill Thompson
Director of Marketing

View this press release online at: http://rwire.com/438008